Evidence map›Paper›PMID 40770305›Full record

ArticleBMC genomics2025

Determination of high-confidence germline genetic variants in next-generation sequencing through machine learning models: an approach to reduce the burden of orthogonal confirmation.

Muqing Yan, Qiandong Zeng, Zhenxi Zhang, Patricia Okamoto, Stanley Letovsky, Angela Kenyon, Natalia Leach, Jennifer Reiner

Abstract read
In one paragraph

Article in BMC genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Muqing YanLabcorp, Burlington, NC, USA. yanm2@labcorp.com.
Qiandong ZengLabcorp, Burlington, NC, USA.
Zhenxi ZhangLabcorp, Burlington, NC, USA.
Patricia OkamotoLabcorp, Burlington, NC, USA.
Stanley LetovskyLabcorp, Burlington, NC, USA.
Angela KenyonLabcorp, Burlington, NC, USA.
Natalia LeachLabcorp, Burlington, NC, USA.
Jennifer ReinerLabcorp, Burlington, NC, USA. reinerj@labcorp.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOrthogonal confirmation of variants identified by next-generation sequencing (NGS) is routinely performed in many clinical laboratories to improve assay specificity. However, confirmatory testing of all clinically significant variants increases both turnaround time and operating costs for laboratories. Improvements to early NGS methods and bioinformatics algorithms have dramatically improved variant calling accuracy, particularly for single nucleotide variants (SNVs), thus calling into question the necessity of confirmatory testing for all variant types. The purpose of this study is to develop a new machine learning approach to capture false positive heterozygous variants (SNVs) from whole exome sequencing (WES) data.

resultsWES variant calls from Genome in a Bottle (GIAB) cell lines and their associated quality features were used to train five different machine learning models to predict whether a variant was a true positive or false positive based on quality metrics. Logistic regression and random forest models exhibited the highest false positive capture rates among the selected models, but GradientBoosting achieved the best balance between false positive capture rates and true positive flag rates. Further assessment using simulated false positive events as well as different combinations of quality features showed that model performance can be refined. Integration of the highest-performing models into a custom two-tiered confirmation bypass pipeline with additional guardrail metrics achieved 99.9% precision and 98% specificity in the identification of true positive heterozygous SNVs within the GIAB benchmark regions. Furthermore, testing on an independent set of heterozygous SNVs (n = 93) detected by exome sequencing of patient samples and cell lines demonstrated 100% accuracy.

conclusionsMachine-learning models can be trained to classify SNVs into high or low-confidence categories with high precision, thus reducing the level of confirmatory testing required. Laboratories interested in deploying such models should consider incorporating additional quality criteria and thresholds to serve as guardrails in the assessment process.

Indexed as

Genetic VariationGerm-Line MutationHigh-Throughput Nucleotide SequencingMachine LearningBoosting Machine Learning AlgorithmsExome SequencingHumansPolymorphism, Single NucleotidePredictive Learning ModelsRandom ForestClinical decision-support toolMachine learningNext generation sequencingSanger confirmation

Identifiers

PMID40770305
PMCPMC12326712

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.